Working memory deficits in schizophrenia are associated with the rs34884856 variant and expression levels of the NR4A2 gene in a sample Mexican population: a case control study

Table 2 Socio-demographic and clinical characteristics of patients and the control group to the rs34884856 promoter variant

	Schizophrenia group			Control group
	3C/3C n = 12	3C/2C + 2C/2C n = 41	p	3C/3C n = 20	3C/2C + 2C/2C n = 62	p
Age, year (±SD)	32.93 (9.3)	33.50 (10.05)	0.984^a	38.7 (12.8)	39.94 (11.47)	0.841 ^a
Gender, n (%) Male	8 (53.3)	26 (68.4)	0.302^b	10 (50)	30 (48.4)	0.900^c
Education, year (±SD)	10.58 (2.57)	12.15 (2.97)	0.103^a	14.05 (3.80)	13.13 (4.38)	0.349 ^a
Family history of schizophrenia (%)	5 (41.7)	12 (29.3)	0.418^b
Age of onset, year (±SD)	20.08 (8.86)	23.35 (6.84)	0.077^a
Disease duration, year (±DS)	11.58 (8.27)	10.68 (9.97)	0.515^a
Typical antipsychotics, n (%)	5 (33.4)	14 (41.7)	0.284^b
SSRI n (%)	1 (8.3)	5 (11.9)	0.718^b
PANSS
Positive symptoms	21.00 (7.50)	20.45 (7.98)	0.994^a
Negative symptoms	26.58 (9.67)	21.94 (7.19)	0.156^a
General symptoms	41.91 (14.82)	37.14 (10.96)	0.323^a
PANSS total	88.66 (28.78)	79.33 (22.17)	0.378^a
Working memory test
WMI	69.25 (10.59)	75.34 (11.80)	0.103^a	87.8 (10.04)	80.7 (14.85)	0.086^a
Arithmetic	4.67 (2.06)	5.63 (2.55)	0.16 ^a	8.65 (2.30)	7.69 (3.19)	0.32^a
DS	4.92 (1.24)	6.19 (2.09)	0.033^a	6.85 (2.11)	6.39 (1.94)	0.40^a
BDS task	2.83 (1.11)	4.09 (1.97)	0.022^a	4.95 (1.70)	4.5 (1.91)	0.278^a
LNS	4.67 (2.01)	6.14 (2.36)	0.051^a	8.50 (1.99)	6.66 (3.08)	0.027^a

Data are presented as mean ± SD
This is a subset of the total sample submitted to cognition tasks, which had genotyping and quantification of NR42 expression levels
SD Standard deviation, n Total participants, 3C Insertion C, 2C Deletion C, SSRI Selective serotonin reuptake inhibitors, PANSS Positive and negative syndrome scale; recessive model, 3C/3C vs 3C/2C + 2C/2C
^aMann-Whitney U, ^bFisher test, ^cChi-squared test

ISSN: 1471-244X